Literature DB >> 12003702

Effects of antihypertensive therapy on sexual activity in hypertensive men.

Roberto Fogari1, Annalisa Zoppi.   

Abstract

Sexual dysfunction has a high prevalence among hypertensive men, and hypertension per se, regardless of drugs, has been suggested to affect sexual function. The available studies have not clarified which factors play a major role in the pathogenesis of sexual dysfunction in hypertensive men. Neurovascular factors, however, seem to be especially important, (in particular defective nitric oxide activity), although hormonal and psychogenic factors cannot be excluded. Further studies are needed to answer the important question of whether erectile dysfunction seen in hypertension may be one expression of vascular disease and target organ damage. The incidence of sexual dysfunction is exacerbated by antihypertensive drug treatment. There is evidence that some classes of drugs, such as diuretics, centrally acting sympatholytic drugs, and b-blockers have a greater impact on sexual function than other classes, such as calcium antagonists and angiotensin converting enzyme inhibitors. Present evidence on the effects of angiotensin II antagonists is limited, but some data suggest that sexual function in men receiving these drugs not only is not altered, but even improves. Since sexual function is an important aspect of quality of life for the individual, it is important in treating hypertension to ensure that the drugs used have the lowest possible potential for causing sexual problems. This ensures the best balance between therapeutic efficacy and quality of life, which is essential for compliance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003702     DOI: 10.1007/s11906-002-0008-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  44 in total

Review 1.  Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease?

Authors:  M E Sullivan; C S Thompson; M R Dashwood; M A Khan; J Y Jeremy; R J Morgan; D P Mikhailidis
Journal:  Cardiovasc Res       Date:  1999-08-15       Impact factor: 10.787

2.  Nitric oxide: a physiologic mediator of penile erection.

Authors:  A L Burnett; C J Lowenstein; D S Bredt; T S Chang; S H Snyder
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

3.  Androgen deprivation in males is associated with decreased central arterial compliance and reduced central systolic blood pressure.

Authors:  F Dockery; C Rajkumar; S Agarwal; J Waxman; C J Bulpitt
Journal:  J Hum Hypertens       Date:  2000-06       Impact factor: 3.012

4.  Hypertension associated with decreased testosterone levels in natriuretic peptide receptor-A gene-knockout and gene-duplicated mutant mouse models.

Authors:  K N Pandey; P M Oliver; N Maeda; O Smithies
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

5.  Impotence during therapy with verapamil.

Authors:  B D King; R Pitchon; E H Stern; P Schweitzer; R R Schneider; I Weiner
Journal:  Arch Intern Med       Date:  1983-06

6.  Change in symptoms of hypertensive patients after referral to hospital clinic.

Authors:  C J Bulpitt; C T Dollery; S Carne
Journal:  Br Heart J       Date:  1976-02

7.  Effect of antihypertensives on sexual function and quality of life: the TAIM Study.

Authors:  S Wassertheil-Smoller; M D Blaufox; A Oberman; B R Davis; C Swencionis; M O Knerr; C M Hawkins; H G Langford
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

8.  Blood pressure and endogenous testosterone in men: an inverse relationship.

Authors:  K T Khaw; E Barrett-Connor
Journal:  J Hypertens       Date:  1988-04       Impact factor: 4.844

9.  Spironolactone and endocrine dysfunction.

Authors: 
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391

10.  Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men.

Authors:  R Virag; P Bouilly; D Frydman
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

View more
  13 in total

1.  Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure.

Authors:  Antonio Ruvolo; Valentina Mercurio; Valeria Fazio; Guido Carlomagno; Teresa Russo; Flora Affuso; Serafino Fazio
Journal:  World J Cardiol       Date:  2010-05-26

2.  The penis as a barometer of endothelial health.

Authors:  Andrew R McCullough
Journal:  Rev Urol       Date:  2003

Review 3.  Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs.

Authors:  Rainer Düsing
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

Review 6.  Erectile dysfunction: symptom or disease?

Authors:  C Foresta; N Caretta; A Aversa; C Bettocchi; G Corona; S Mariani; M Rossato
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

Review 7.  Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

Authors:  Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

8.  A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice.

Authors:  M P J Nicolai; S S Liem; S Both; R C M Pelger; H Putter; M J Schalij; H W Elzevier
Journal:  Neth Heart J       Date:  2014-01       Impact factor: 2.380

9.  Irbesartan improves arterial compliance more than lisinopril.

Authors:  Khalid Ali; Chakravarthi Rajkumar; Francesco Fantin; Rebekah Schiff; Christopher J Bulpitt
Journal:  Vasc Health Risk Manag       Date:  2009-07-14

Review 10.  The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-06-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.